Terns Pharmaceuticals, Inc. 4 SEC Filings

Filed On	Filing
05 May 2026	Form 4: Azelby Robert, Director Disposed of 91,697 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Turner Heather D, Director Disposed of 110,697 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Tripuraneni Radhika, Director Disposed of 190,030 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Quigley Jill M., Director Disposed of 147,309 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Kindler Jeffrey B, Director Disposed of 208,505 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Fellows David A, Director Disposed of 221,136 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Kuriakose Emil, Chief Medical Officer Disposed of 24,562 shares (Tender Offer) ($1.3M) · Returned 81,953 shares to the issuer ($4.34M) · Disposed of 1,115,000 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Gengos Andrew, Chief Financial Officer Disposed of 40,503 shares (Tender Offer) ($2.15M) · Returned 68,750 shares to the issuer ($3.64M) · Disposed of 887,500 Stock Option (Right to Buy) (Disposition to Issuer)
05 May 2026	Form 4: Burroughs Amy L., Director Disposed of 154,933 shares (Tender Offer) ($8.21M) · Returned 150,000 shares to the issuer ($7.95M) · Disposed of 2,505,534 Stock Option (Right to Buy) (Disposition to Issuer)
02 Apr 2026	Form 4: Kuriakose Emil, Chief Medical Officer Sold 942 shares ($49.7K)
17 Mar 2026	Form 4: Burroughs Amy L., Director Received 14,583 shares by exercise or conversion ($67.7K) · Sold 14,583 shares ($681K)
18 Feb 2026	Form 4: Burroughs Amy L., Director Received 14,583 shares by exercise or conversion ($67.7K) · Sold 14,583 shares ($572K)
02 Feb 2026	Form 4: Tripuraneni Radhika, Director Granted 1,697 Stock Option (Right to Buy)
02 Feb 2026	Form 4: Azelby Robert, Director Granted 1,697 Stock Option (Right to Buy)
02 Feb 2026	Form 4: Quigley Jill M., Director Granted 1,697 Stock Option (Right to Buy)
02 Feb 2026	Form 4: Turner Heather D, Director Granted 1,697 Stock Option (Right to Buy)
02 Feb 2026	Form 4: Kindler Jeffrey B, Director Granted 1,697 Stock Option (Right to Buy)
02 Feb 2026	Form 4: Fellows David A, Director Granted 2,828 Stock Option (Right to Buy)
16 Jan 2026	Form 4: Kuriakose Emil, Chief Medical Officer Received 56,250 shares as a grant or award · Granted 112,500 Stock Option (Right to Buy)
16 Jan 2026	Form 4: Gengos Andrew, Chief Financial Officer Received 68,750 shares as a grant or award · Granted 137,500 Stock Option (Right to Buy)

Comments